ClinicalTrials.gg
RecruitingNCT07483554Updated Jun 3, 2026

IBI343 in Combination Therapy for Advanced Malignant Solid Tumors

A Phase 2 interventional study of IBI343,Gemcitabine, Albumin-bound Paclitaxel in CLDN18.2 Positive, Gastric/Gastroesophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
389
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

A Phase II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of IBI343 in combination therapy for patients with advanced malignant solid tumors.To evaluate the efficacy and safety of IBI343 in combination therapy for patients with advanced malignant solid tumors.Enrollment of subjects with advanced gastric/gastroesophageal junction adenocarcinoma positive for CLDN18.2, and subjects with pancreatic ductal adenocarcinoma positive for CLDN18.2.

02

Conditions studied

  • CLDN18.2 Positive
  • Gastric/Gastroesophageal Junction Adenocarcinoma
  • Pancreatic Ductal Adenocarcinoma
03

In context

Lead sponsor

Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed written , willing and able to comply with the protocol-specified visits and related procedures.
  2. At least one according to the (RECIST v1.1).
  3. Age ≥ 18 years, no gender restrictions.
  4. An (ECOG) performance status score of 0 or 1.
  5. Expected survival ≥ 12 weeks.
  6. Adequate bone marrow and organ function.
  7. Female subjects of or male subjects whose partners are of childbearing potential must use effective throughout the treatment period and for 6 months after the end of treatment.
  8. Confirmed CLDN18.2 positive by central laboratory pathological tissue testing.

Exclusion criteria

Exclusion criteria:

  1. Currently participating in another interventional clinical study, except for observational (non-interventional) clinical studies or those in the survival follow-up phase of an interventional study.
  2. Received treatment with a strong cytochrome P450 3A4 () inhibitor within 2 weeks or 5 half-lives (whichever is longer) prior to the first dose of the drug.
  3. Received the last anti-tumor treatment within 4 weeks or 5 half-lives of the anti-tumor therapy (whichever is shorter) before the first dose of the investigational drug.
  4. Received therapeutic or palliative radiotherapy within 2 weeks prior to the first dose of the investigational drug.
  5. Underwent biliary stent placement within 7 days prior to the first dose of the investigational drug.
  6. Planning to receive other anti-tumor treatments during the period of treatment with the investigational drug.
  7. Received any within 4 weeks prior to the first dose of the investigational drug or planning to receive any live vaccine during the study.
  8. Underwent major surgery within 4 weeks prior to the first dose of the investigational drug, or has unhealed wounds, ulcers, or fractures; or plans to undergo major surgery during the study.
  9. Has not recovered from toxicity caused by previous treatment to grade 0 or 1 according to v5.0 prior to the first dose of the investigational drug.
  10. History of gastrointestinal perforation and/or fistula within 6 months prior to the first dose of the investigational drug that was not cured by surgical treatment.
  11. Presence of pyloric obstruction and/or persistent recurrent vomiting.
  12. Post-procedure of stent implantation in the digestive tract or trachea.
  13. Symptomatic central nervous system .
  14. Bone metastasis with risk of paraplegia.
  15. Interstitial lung disease requiring treatment, or history of interstitial lung disease, non-infectious pneumonia, severe impairment of pulmonary function, or uncontrolled pulmonary disease such as pulmonary fibrosis, severe radiation pneumonitis, acute lung injury, etc., or suspected of having these diseases during the screening period.
  16. Presence of uncontrolled disease.
  17. History of other primary malignant tumors.
  18. Known history of immunodeficiency.
  19. History of allogeneic organ transplantation and hematopoietic stem cell transplantation.
  20. Previous treatment with topoisomerase inhibitor-based antibody-drug conjugates.
  21. For subjects receiving drug treatment, a history of allergy to the corresponding drug or formulation.
  22. For subjects receiving drug treatment, for the corresponding drug.
  23. For subjects receiving drug treatment, a history of permanent discontinuation of the corresponding drug due to related adverse reactions.
  24. Pregnant or lactating female subjects.
  25. Other conditions deemed unsuitable for participation in this study by the investigator.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
389 participants (estimated)

Study arms

  • Experimental
    Experimental Arm

    Drug: IBI343,Gemcitabine, Albumin-bound Paclitaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) evaluated according to RECIST v1.1

    Time frame: Up to 24 months

  2. Incidence of Adverse Events (AE)

    Time frame: Up to 24 months

  3. Incidence of treatment-emergent adverse Events (TEAE)

    Time frame: Up to 24 months

  4. Incidence of adverse events of Special Interest (AESI)

    Time frame: Up to 24 months

  5. Incidence of serious adverse events (SAE)

    Time frame: Up to 24 months

  6. Number of participants with abnormal laboratory tests results

    Time frame: Up to 24 months

  7. Number of subjects with clinically significant changes in physical examination results

    Clinically significant abnormal physical examination findings reported by the investigator.

    Time frame: Up to 24 months

  8. Number of subjects with clinically significant changes in vital signs

    Vital signs including body temperature, pulse, respiratory rate, SpO2 and blood pressure

    Time frame: Up to 24 months

Secondary outcomes

  1. Duration of Response (DoR) evaluated according to RECIST v1.1

    Time frame: Up to 24 months

  2. Disease Control Rate (DCR) evaluated according to RECIST v1.1

    Time frame: Up to 24 months

  3. Time to Response (TTR) evaluated according to RECIST v1.1

    Time frame: Up to 24 months

  4. Progression-Free Survival (PFS) evaluated according to RECIST v1.1

    Time frame: Up to 24 months

  5. Overall Survival (OS)

    Time frame: Time to death

  6. Area under the concentration-time curve for subjects receiving IBI343 treatment

    Time frame: Up to 24 months

  7. Peak concentration for subjects receiving IBI343 treatment

    Time frame: Up to 24 months

  8. Time to peak concentration for subjects receiving IBI343 treatment

    Time frame: Up to 24 months

  9. Trough concentration for subjects receiving IBI343 treatment

    Time frame: Up to 24 months

  10. Clearance for subjects receiving IBI343 treatment.

    Time frame: Up to 24 months

  11. Apparent volume of distribution for subjects receiving IBI343 treatment.

    Time frame: Up to 24 months

  12. Half-life for subjects receiving IBI343 treatment.

    Time frame: Up to 24 months

  13. Positive rate of anti-drug antibodies

    Time frame: Up to 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Mar 2028, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2026
First posted
Mar 19, 2026
StartActual
Apr 20, 2026
Primary completionEst.
Mar 31, 2028
CompletionEst.
Mar 31, 2028
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07483554
Responsible party
Sponsor
First posted
Mar 19, 2026
Start date
Apr 20, 2026
Primary completion
Mar 31, 2028 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Jun 3, 2026

Study contacts

Shuang Han
Contact
shuang.han@innoventbio.com
+86 512 6956 6088

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Arcotatug tavatecan · Gemcitabine · Albumin-Bound Paclitaxel

Start the discussion